论文部分内容阅读
目的研究孟鲁司特钠片(顺尔宁)联合布地奈德福莫特罗粉吸入剂(信必可都保)与单用信必可都保在治疗支气管哮喘疗效上的差异。方法 64例支气管哮喘患者,按照随机分配方式将其分为实验组和比较组,每组32例。比较组患者单纯采用信必可都保进行治疗,实验组则采用顺尔宁联合信必可都保的方式进行治疗。观察并对比两组患者的治疗效果。结果实验组临床总有效率90.63%明显高于比较组68.75%,差异具有统计学意义(P<0.05)。治疗前两组患者的肺功能指标比较差异无统计学意义(P>0.05);治疗后,实验组患者肺功能指标均明显优于比较组,差异具有统计学意义(P<0.05)。结论顺尔宁联合信必可都保的方式对于支气管哮喘患者具有显著的治疗效果,值得广泛应用推广。
Objective To study the difference of the curative effect between montelukast sodium tablets (sirolimus) combined with budesonide formoterol powder inhalers (aciborubicin) and single-use bevacizumab in the treatment of bronchial asthma. Methods Sixty-four patients with bronchial asthma were randomly divided into experimental group and control group, with 32 cases in each group. The patients in the comparison group were treated with Xinbiddu only, while the experimental group were treated by the combination of Shunde Ningxinxinbao and Dudubao. Observed and compared the treatment effect of two groups of patients. Results The total clinical effective rate was 90.63% in the experimental group was significantly higher than 68.75% in the comparison group, the difference was statistically significant (P <0.05). Before treatment, there was no significant difference in lung function between the two groups (P> 0.05). After treatment, the indexes of pulmonary function in the experimental group were significantly better than those in the comparison group (P <0.05). Conclusions The combination of Shundeling and Xinbibuxin can have a significant therapeutic effect on patients with bronchial asthma, which is worthy of wide application and promotion.